SFO
GILD icon

Stokes Family Office’s Gilead Sciences GILD Stock Holding History

Stokes Family Office’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$224K Sell
1,776
-504
-22% -$66.4K 0.03% 256
2026
Q1 		$318K Sell
2,280
-453
-17% -$63.4K 0.03% 229
2025
Q4 		$335K Buy
2,733
+604
+28% +$73.4K 0.03% 238
2025
Q3 		$236K Buy
2,129
+47
+2% +$5.34K 0.02% 240
2025
Q2 		$231K Buy
2,082
+5
+0.2% +$532 0.02% 216
2025
Q1 		$233K Buy
+2,077
New +$214K 0.03% 216
2023
Q3 		– Sell
-2,606
Closed -$201K – 349
2023
Q2 		$201K Buy
2,606
+143
+6% +$11.4K 0.02% 301
2023
Q1 		$204K Sell
2,463
-217
-8% -$18K 0.03% 277
2022
Q4 		$230K Buy
+2,680
New +$212K 0.03% 246

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Stokes Family Office's GILD Position: Q2 2026 in Review

Stokes Family Office reduced its Gilead Sciences (GILD) stake by 22% in Q2 2026, selling an estimated $66.4K and leaving 1,776 shares worth $224K. The position accounts for 0.03% of the portfolio, ranked #256.

Stokes Family Office first reported a position in GILD in Q4 2022 and has held it in 9 quarters since. The position peaked at $335K in Q4 2025. 2,284 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Stokes Family Office held 1,776 shares of Gilead Sciences worth $224K as of Q2 2026.
  • Stokes Family Office sold 504 Gilead Sciences shares in Q2 2026, an estimated $66.4K.
  • Gilead Sciences made up 0.03% of Stokes Family Office's portfolio in Q2 2026, its #256 holding.
  • Stokes Family Office first reported a position in Gilead Sciences in Q4 2022 and has held it in 9 quarters since.
  • Stokes Family Office's Gilead Sciences position peaked at $335K in Q4 2025.
  • 2,284 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Stokes Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.